Breast Cancer Diagnostic and Drug Technologies: Global Markets

  • ID: 4541505
  • Report
  • Region: Global
  • 154 Pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 6
This Report Highlights Current and Future Market Potential for Breast Cancer Therapeutics Along with a Detailed Analysis of the Competitive Environment

FEATURED COMPANIES

  • Abbott Laboratories
  • Astrazeneca Plc
  • CCC Diagnostics Llc
  • Eli Lilly And Company
  • Nanostring Technologies
  • Pfizer, Inc.
  • MORE

Report Scope:

The objective of the current report is to provide the readers with updated market estimates for the diagnostics and therapeutics market. This report also highlights current and future market potential for breast cancer therapeutics along with a detailed analysis of the competitive environment, pipeline drugs, blockbuster drugs and other diagnostic and therapeutic development.

The report includes breast cancer epidemiology including global and regional prevalence, incidence and mortality rates; regulatory environment for markers and therapeutics along with recent regulatory approvals, current and new technologies, market projections and market share for key market players. Market drivers, trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report.

The report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA approved drugs for treating breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report.

This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics along with market share of therapeutics by drug class (HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors and hormone receptors), geographic market segmentation of the overall market and global market share by company with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for the year 2016, as the base year, 2017 and a forecast for 2022.

Report Includes:

  • 36 data tables and 47 additional tables
  • Country-specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, China, India, Japan, and South Korea
  • Estimated revenue of the global mammography, biopsy, companion diagnostic IVD, and therapeutic markets by various segments and subsegments
  • Identification of key market dynamics, trends, and opportunities
  • Insight into mergers and acquisitions, new product developments, strategies, and research-and-development activities
  • Comprehensive profiles of major players in the market, including Abbvie, Inc., Abbott Laboratories, Bristol-Myers Squibb Company, Dako, Eli Lilly and Company, Novartis International AG, and Pfizer, Inc.

Membership Price:

Contact us for membership pricing.

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Astrazeneca Plc
  • CCC Diagnostics Llc
  • Eli Lilly And Company
  • Nanostring Technologies
  • Pfizer, Inc.
  • MORE

1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related Reports

2 Summary and Highlights

3 Market and Technology Background

  • Introduction
  • Classification of Breast Cancer by Type
  • Non-invasive Breast Cancers
  • Ductal Carcinoma Insitu (DCIS)
  • Lobular Carcinoma Insitu (LCIS)
  • Invasive Breast Cancers
  • Invasive (or Infiltrating) Ductal Carcinoma (IDC)
  • Invasive (or Infiltrating) Lobular Carcinoma (ILC)
  • Tubular Carcinoma (TC)
  • Invasive Cribriform Carcinoma
  • Mucinous Carcinoma
  • Invasive Papillary Carcinoma
  • Inflammatory Breast Cancer
  • Paget's Disease of the Breast
  • Cytosarcoma Phyllodes
  • Metastatic Breast Cancer (MBC)
  • Molecular Subtypes of Breast Cancer
  • Luminal A
  • Luminal B Types
  • HER2 Type
  • HER2-Amplified
  • Triple-Negative Breast Cancer (TNBC) or Basal Type
  • Normal-Like
  • Causes, Indications and Risk Factors
  • Symptoms
  • Breast Cancer Staging
  • Epidemiology
  • United States Breast Cancer Incidence

4 Breast Cancer Market Dynamics

  • Market Drivers
  • Increasing Incidence of Breast Cancer Worldwide
  • Focused Research and Development for Novel Drugs
  • High Increase in Healthcare Expenditure and Funding
  • Increasing Breast Cancer Screening Programs
  • Favorable Reimbursement for Screening and Diagnosis
  • Market Restraints
  • Pricing Pressure Experienced by Innovators
  • High Cost Associated with New Drug Development and Clinical Trials
  • Regulatory and Reimbursement Hurdles
  • Market Opportunity
  • Rising Female Population in Asia Pacific
  • Increased Demand for Technology Innovation
  • Technological Advancement in the Drug Sector
  • Emergence of Breast Cancer Predictive Tests
  • Opportunity for Generic Manufacturers to Exploit Patents at the Verge of Expiry
  • Breast Cancer Therapy: Unmet Needs

5 Market Breakdown by Technology

  • Breast Cancer Diagnostic Market
  • Mammography
  • Latest Developments
  • Mammography Procedure Volumes
  • Global Mammography Market
  • Limitations of Mammography
  • Breast Biopsy Device Market
  • Introduction
  • Global Breast Biopsy Device Market
  • Breast Cancer Predictive Diagnostic Market
  • Introduction
  • Predictive Diagnostic Tests
  • Global Breast Cancer Companion Diagnostic Test Market

6 Market Breakdown by Drug Class

  • Overview
  • Breast Cancers Drug Classes
  • Breast Cancer Market
  • Antimetabolites
  • Tanaxanes
  • Aromatase Inhibitors
  • HER2 Inhibitor
  • Hormone Therapy

7 Market Breakdown by Region

  • Breast Cancer Incidence by Region
  • Global Market by Region
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa (MEA)
  • South America

8 Regulatory Scenario

  • Breast Cancer Diagnostics and Therapeutics Regulatory Challenges
  • North America
  • Food and Drug Administration (FDA)
  • Europe
  • Asia-Pacific
  • Japan
  • China
  • South America
  • Brazil

9 Patent Review/New Developments

  • Patent Review
  • Companion Diagnostics
  • Patent Expiration

10 Reimbursement Landscape

  • Introduction
  • United States
  • Mammography Procedure Reimbursement
  • Biopsy Procedure Reimbursement
  • Breast Cancer Drugs Reimbursement
  • Germany
  • Mammography Procedure Reimbursement
  • Biopsy Procedure Reimbursement
  • Breast Cancer Drugs Reimbursement
  • Mexico
  • Brazil

11 Pipeline Analysis

  • Introduction
  • Breast Cancer Therapeutics Pipeline by Phases
  • Phase III
  • Phase II
  • Phase I
  • Breast Cancer Therapeutics Pipeline by Company
  • AbbVie, Inc.
  • Array BioPharma, Inc.
  • AstraZeneca
  • Belrose Pharmaceuticals
  • Beta Pharma
  • BioMarin Pharmaceuticals
  • CASI Pharmaceuticals, Inc.
  • Celgene
  • Celldex Therapeutics
  • Celsion
  • Clovis
  • Clovis Eli Lilly
  • Novartis
  • Pfizer
  • Puma Biotechnology
  • Roche
  • Syndax Pharmaceuticals
  • Tesaro Inc.

12 Competitive Landscape

  • Major Mammography Equipment Market Players
  • Major Breast Cancer Drug Market Players

13 Company Profiles

  • ABBVIE INC.
  • Company Overview
  • Financials
  • Products
  • Developments and Strategies
  • ABBOTT LABORATORIES
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • ASTRAZENECA PLC
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategy
  • ATOSSA GENETICS INC.
  • Overview
  • Financials
  • Products
  • Developments and Strategies
  • BRISTOL-MYERS SQUIBB COMPANY
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • CCC DIAGNOSTICS LLC
  • Company Overview
  • Product Information
  • DAKO
  • Company Overview
  • Product Information
  • ELI LILLY AND COMPANY
  • Company Overview
  • Financials
  • F. HOFFMANN-LA ROCHE AG
  • Company Overview
  • NANOSTRING TECHNOLOGIES
  • Company Overview
  • NOVARTIS INTERNATIONAL AG
  • Company Overview
  • PFIZER, INC.
  • Company Overview
  • Financials
  • PUMA BIOTECHNOLOGY INC.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • SANOFI S.A.
  • Overview
  • Financials
  • Development and Strategies

14 Abbreviations

List of Tables
Summary Table: Global Breast Cancer Diagnostic and Drug Market, by Technology, Through 2022
Table 1: Difference between Normal and Benign Breast Cancer Cells
Table 2: New Female Breast Cancer Cases and Deaths in the United States, by Age, 2017
Table 3: Histological Types, Frequency of Occurrence and Rate of Survival
Table 4: Different Mucinous Carcinoma
Table 5: Critical Steps and Genes Involved in Breast Cancer Metastasis
Table 6: Characteristics of Molecular Subtypes of Invasive Breast Cancer
Table 7: Local-Regional Recurrence, by Molecular Subtype
Table 8: Local-Regional Recurrence, by Molecular Subtypes
Table 9: Local-Regional Recurrence, by Molecular Subtype
Table 10: Global Breast Cancer Incidence, 2016-2021
Table 11: Global Breast Cancer Incidence and Mortality, 2008
Table 12: New Breast Cancer Cases, by Region, 2009 and 2012
Table 13: New Breast Cancer Cases in the United States, by Gender, 2010-2019
Table 14: New Female Breast Cancer Cases and Deaths in the United States, by Age, 2011
Table 15: Breast Cancer Incidence and Mortality in the United States, 2011
Table 16: Global Breast Cancer Incidence, by Country, Through 2012
Table 17: Asia-Pacific Breast Cancer Incidence and 40+ Female Population, Through 2017
Table 18: List of Breast Cancer Drugs and Their Patent Exclusivity Period
Table 19: Femara Revenue, 2009-2015
Table 20: Indicative List of Available Generic Versions of Letrazole
Table 21: Global Mammography Market, by Region, Through 2022
Table 22: Global Mammography Market, by Device Type, Through 2022
Table 23: Global Breast Cancer Biopsy Device Market, by Region, Through 2022
Table 24: Indicative List of Available Breast Cancer Prognostic, Diagnostic, Monitoring and Grading Diagnostics Tests, 2017
Table 25: Different Classes of Breast Cancer Drugs
Table 26: Global Breast Cancer Drugs Market, by Drug Class, Through 2022
Table 27: Global Aromatase Inhibitor Drugs Market, by Drug Type, Through 2022
Table 28: Global HER2 Inhibitor Drugs Market, by Drug Type, Through 2022
Table 29: Global Hormone Receptor Drugs Market, by Drug Type, Through 2022
Table 30: Global Breast Cancer Therapy Market, by Region, Through 2022
Table 31: North America Breast Cancer Therapy Market, by Country, Through 2022
Table 32: European Breast Cancer Therapy Market, by Country, Through 2022
Table 33: Breast Cancer Incidence, Men and Women
Table 34: Asia-Pacific Breast Cancer Therapy Market, by Country, Through 2022
Table 35: List of FDA-Approved Drugs, 1996-2017
Table 36: List of FDA-approved Companion Diagnostics, 2018
Table 37: List of Breast Cancer Drugs Approved by the EMA, 1995-2018
Table 38: Companion Diagnostics Patent Review, 2015-2017
Table 39: Breast Cancer Therapeutics Patent Review, 2010-2018
Table 40: Patent Expiration of Breast Cancer Drugs
Table 41: United States Mammography Reimbursement, 2017
Table 42: United States Biopsy Procedure Reimbursement, 2017
Table 43: Medicare Part B: Breast Cancer Drugs Payment Limit, 2018
Table 44: Mammography In-Patient Procedure Reimbursement
Table 45: In-Patient Biopsy Procedure Codes
Table 46: Breast Cancer Drugs Gemzar and Herceptin Reimbursement, Germany, 2017
Table 47: Indicative List of Phase III Breast Cancer Therapy Pipeline
Table 48: Indicative List of Phase II Breast Cancer Therapy Pipeline
Table 49: Indicative List of Phase I Breast Cancer Therapy Pipeline
Table 50: AbbVie, Inc.: Pipeline Drugs
Table 51: Array BioPharma, Inc.: Pipeline Drugs
Table 52: AstraZeneca: Pipeline Drugs
Table 53: Belrose Pharmaceuticals: Pipeline Drugs
Table 54: Beta Pharma: Pipeline Drugs
Table 55: BioMarin Pharmaceuticals: Pipeline Drugs
Table 56: CASI Pharmaceuticals, Inc.: Pipeline Drugs
Table 57: Celgene: Pipeline Drugs
Table 58: Celldex Therapeutics: Pipeline Drugs
Table 59: Celsion: Pipeline Drugs
Table 60: Clovis: Pipeline Drugs
Table 61: Eli Lilly: Pipeline Drugs
Table 62: Novartis: Pipeline Drugs
Table 63: Pfizer, Inc.: Pipeline Drugs
Table 64: Puma Biotechnology: Pipeline Drugs
Table 65: Roche: Pipeline Drugs
Table 66: Syndax Pharmaceuticals: Pipeline Drugs
Table 67: Tesaro, Inc.: Pipeline Drugs
Table 68: AbbVie, Inc.: Company Net Revenue, 2014-2017
Table 69: Abbott Laboratories: Company Net Revenue, 2014-2017
Table 70: Abbott Laboratories: Marketed Products, 2016
Table 71: AstraZeneca Plc.: Company Net Revenue, 2014-2017
Table 72: AstraZeneca Plc.: Revenue, by Segment, Through 2016
Table 73: AstraZeneca Plc.: Marketed Products, 2016
Table 74: Bristol-Myers Squibb Company: Net Revenue, 2014-2016
Table 75: Eli Lilly and Company: Net Revenue, 2014-2017
Table 76: Eli Lilly and Company: Net Revenue, by Segment, 2014-2016
Table 77: Eli Lilly and Company: Revenue, by Oncology Drugs, 2014-2016
Table 78: F. Hoffmann-La Roche, Ltd.: Net Revenue, by Segment, Through 2017
Table 79: Novartis International AG: Net Revenue, by Segment, Through 2017
Table 80: Pfizer, Inc.: Net Revenue, 2014-2016
Table 81: Pfizer, Inc.: Oncology Drugs Revenue, 2015-2016
Table 82: Abbreviations Used in Breast Cancer Diagnostic and Drug Technology

List of Figures
Summary Figure: Global Breast Cancer Diagnostic and Drug Market, by Technology, 2016-2022
Figure 1: Breast Anatomy of Normal and Cancerous Ducts and Lobules
Figure 2: Market Share of Invasive and Non-invasive Breast Cancer, United States, 2017
Figure 3: Histopathological Classification of Breast Cancer
Figure 4: Non-invasive Breast Cancer Cases in the United States, 2015
Figure 5: New Cases of Invasive Breast Cancer in the United States, 2015
Figure 6: Invasive Breast Cancers Market Share, by Type
Figure 7: Occurrence of Molecular Subtypes
Figure 8: Global Burden of Breast Cancer
Figure 9: National Cancer Institute Research Funding, 2011-2016
Figure 10: NCRI Breast Cancer Research Spending, 2010-2017
Figure 11: Total Number of Mammography Procedures in the United States, Canada and Mexico, 2010-2015
Figure 12: Total Number of Mammography Procedures in Europe, 2010-2015
Figure 13: Total Number of Mammography Procedures in Asia-Pacific, 2010-2015
Figure 14: Global Mammography Market, 2016-2022
Figure 15: Global Breast Cancer Companion Diagnostic Market, 2016-2022
Figure 16: Global Breast Cancer Drugs Market Share, by Drug Class, 2016
Figure 17: Global Aromatase Inhibitor Drugs Market, by Drug Type, 2016-2022
Figure 18: Global HER2 Inhibitor Drugs Market, by Drug Type, 2016-2022
Figure 19: Global Hormone Receptor Drugs Market, by Drug Type, 2016-2022
Figure 20: Global Breast Cancer Incidence, by Region, 2012
Figure 21: Middle East and Africa Breast Cancer Therapy Market, by Country, 2016-2022
Figure 22: South America Breast Cancer Therapy Market, by Country, 2016-2022
Figure 23: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 24: Medical Device PMDA Approval Procedure
Figure 25: Reimbursement of Drugs in Germany
Figure 26: Global Market Share of Mammography Equipment, by Company, 2016
Figure 27: Global Market Share of Breast Cancer Drugs, by Company, 2016
Figure 28: AbbVie, Inc.: Net Revenue, 2013-2016
Figure 29: AbbVie, Inc.: Lupron Sales, 2014-2016
Figure 30: Abbott Laboratories: Revenue Share, by Segment, 2016
Figure 31: AstraZeneca Plc.: Revenue, by Drug, 2014-2016
Figure 32: Bristol-Myers Squibb Company: Revenue Share, by Region, 2016
Figure 33: Bristol-Myers Squibb Company: Revenue Share, by Business Segment, 2016
Figure 34: Eli Lilly and Company: Revenue Share, by Region, 2016
Figure 35: F. Hoffmann-La Roche, Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 36: F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, 2014-2017
Figure 37: F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, by Region, 2016
Figure 38: Novartis International AG: Breast Cancer Drugs Revenue, 2014-2016
Figure 39: Pfizer, Inc.: Breast Cancer Drugs Revenue, 2015 and 2016
Figure 40: Aromasin Revenue, 2010-2013
Figure 41: Sanofi S.A.: Pharmaceuticals Segment Revenue Share, by Therapy, 2017
Figure 42: Sanofi S.A.: Breast Cancer Drug Taxotere Revenue, 2011-2017

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Astrazeneca Plc
  • CCC Diagnostics Llc
  • Eli Lilly And Company
  • Nanostring Technologies
  • Pfizer, Inc.
  • MORE

In women, breast cancer is the second leading cause of cancer death. Per World Health Organization (WHO) statistics, about one-third of these cancer fatalities can be decreased through earlier detection and treatment. Early breast cancer treatment and detection have improved the five-year survival rate for women diagnosed with cancer to nearly 80%. The breast cancer diagnostic and drug technology markets include a variety of products approved for breast cancer treatment, including hormonal therapies, chemotherapeutic drugs, combinations and targeted therapies. Many
side effects, adverse reactions and safety concerns have come up associated with newer, innovative drugs. Therefore, drugs with improved safety and efficacy are needed to treat breast cancer effectively.

In countries such as the United States, the chance of a woman developing breast cancer during her lifetime has increased. An estimated 522,000 women died from breast cancer globally in the year 2012. Rising healthcare costs associated with breast cancer treatment, have left several patients either uninsured or with less meaningful coverage than they need and deserve.

With the anticipated increase in the number of breast cancer cases, breast cancer research and development is attractive and requires attention from pharmaceutical firms. Drugs for breast cancer comprise a dynamic and growing global market. Roche is predicted to account for more than half of the market. Common detection techniques for breast cancer are diagnostic mammography and ultrasound followed by a biopsy. Studies clearly show that breast cancer treatment is far more effective when cancer is detected at an early stage. Therefore, specific and effective diagnostic tools are needed for early diagnosis.

Reasons for Doing This Study:

There has been a significant improvement in understanding the molecular and cellular mechanism of cancer metastasis. As the incidence of breast cancer is increasing globally, government agencies and research firms are focused on developing new diagnostics, predictive diagnostics and predictive tools to identify breast cancer in early stages where patient survival is increased. Several targeted therapies have evolved over the last decades and several others are likely to reach the market in the next five years. Due to increased investment, raising cancer awareness and research and development activities the breast cancer diagnostic and therapy market dynamics are expected to change during the forecast period. The intent of this study is to provide readers with detailed information regarding the latest innovative developments for early identification of breast cancer and targeted therapy. This study looks at different classes of available drug types and their applications. This report also identifies potential pipeline molecules which could translate into clinical practice.

Note: Product cover images may vary from those shown
5 of 6
  • Abbott Laboratories
  • Abbvie Inc.
  • Astrazeneca Plc
  • Atossa Genetics Inc.
  • Bristol-Myers Squibb Company
  • CCC Diagnostics Llc
  • Dako
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ag
  • Nanostring Technologies
  • Novartis International Ag
  • Pfizer, Inc.
  • Puma Biotechnology Inc.
  • Sanofi S.A.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll